Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Diabetes treatment linked to increased blood pressure in animal study

11.07.2002

A report in the July issue of the Journal of Clinical Investigation has found that a group of drugs currently under development for the treatment of Type II diabetes caused both increased heart rate and elevated blood pressure in animal studies.

These new findings regarding glucagon-like peptide (GLP-1) receptor agonists suggest that the brain’s GLP-1 system has the ability to affect autonomic function, leading to changes in heart rate and blood pressure.

A naturally occurring hormone that is produced by cells lining the intestine, GLP-1 was first targeted as a diabetes treatment about 15 years ago, according to the study’s senior author Joel Elmquist, D.V.M., Ph.D., a neuroscientist and endocrinologist at Beth Israel Deaconess Medical Center and Associate Professor of Neurology and Medicine at Harvard Medical School.

"GLP-1 stimulates insulin secretion and controls feeding and drinking behavior, and also regulates neuroendocrine responses to agents that elicit illness-like behaviors," he explains. "The effect on insulin secretion made the hormone an obvious target for treating diabetes."

Diabetes develops when the body fails to either produce or to properly use insulin, a hormone necessary to convert food – including sugars and starches – into energy. Type II diabetes accounts for the majority of cases of the disease, and is a huge public health problem: As many as 16 million individuals in the United States have Type II diabetes, which puts them at risk for a number of serious complications, including stroke and heart disease.

Although diabetes can often be controlled through diet, exercise and existing medications, the magnitude of the problem has given rise to the development of a number of new drugs to better manage the disease, including the GLP-1 agonists. These agents, which are currently being tested in clinical trials, work by targeting the rate of gastric emptying and by stimulating insulin secretion from islet cells in the pancreas.

Circulating levels of the naturally occurring GLP-1 hormone in health individuals are low when the body is in a fasting state, according to Elmquist. After a person has eaten, GLP-1 levels rise, only to fall within minutes as a result of enzymatic activity. In fact, he adds, continuous infusion of GLP-1 does not increase either blood pressure or heart rate in humans with Type II diabetes.

However, in drug form, GLP-1 analogs such as EXENDIN-4 have a far more potent and long-lasting influence. In the studies on rodents conducted in Elmquist’s lab, the researchers demonstrated that EXENDIN-4 – which is being tested as a therapeutic agent – activated several key autonomic regulatory sites in the brain, leading to increased heart rate and blood pressure in the animals.

"Despite accumulating data linking GLP-1 to autonomic and neuroendocrine responses, the pathways [responsible] for the actions were previously not well understood," explains Elmquist. "Although these new findings in animals will need to be studied further, especially in diabetic models, this research suggests that the central GLP-1 system can regulate sympathetic outflow including raising heart rate and blood pressure."

###

Study co-authors include Beth Israel Deaconess researchers Hiroshi Yamamoto, M.D., Ph.D., Charlotte Lee, M.S., Jacob Marcus, B.S., Marisol Lopez, Ph.D., and Anthony Hollenberg, M.D.; Todd Williams, Ph.D., and J. Michael Overton, Ph.D., of Florida State University; and Laurie Baggio, Ph.D., and co-principal investigator Daniel Drucker, M.D., of the Banting and Best Diabetes Center at the University of Toronto.

The study was funded by grants from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institutes of Health.

Beth Israel Deaconess Medical Center is a major patient care, research and teaching affiliate of Harvard Medical School and a founding member of CareGroup Healthcare System. Beth Israel Deaconess is the third largest recipient of National Institutes of Health funding among independent U.S. teaching hospitals.

Bonnie Prescott | EurekAlert

More articles from Health and Medicine:

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

nachricht Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

Leipzig HTP-Forum discusses "hydrothermal processes" as a key technology for a biobased economy

12.07.2017 | Event News

 
Latest News

Researchers create new technique for manipulating polarization of terahertz radiation

20.07.2017 | Information Technology

High-tech sensing illuminates concrete stress testing

20.07.2017 | Materials Sciences

First direct observation and measurement of ultra-fast moving vortices in superconductors

20.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>